[1] MEIER D A, BRILL D R, BEEKR D R, et al. Procedure guideline for therapy of thyroid disease with 131I[J]. J Nucl Med, 2002,
43(6): 856-861.
[2] KAPLAN M M, MEIER D A, DWORKIN H J. Treatment of hyperthyroism with radioactive iodine[J]. Endocrinol Metab Clin Ncth Am, 1998, 27(6): 205-223.
[3] 中华医学会内分泌学分会《中国甲状腺疾病诊断指南》编写组. 中国甲状腺疾病诊断指南-甲状腺功能亢进症[J]. 中华内科杂志, 2007, 46(12): 876-882.
[4] ANGUSTI T, CODEGONE A, PELLEROTP R, et al. Thyriod cancer prevalence after radiodine treament of hyperthyroidism[J]. J Nucl Med, 2000, 41(6): 1003-1009.
[5] The American Thyroid Association(ATA), American Association of Clinical Endocrinologists(AACE). Hyperthyroidismandother causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American of Clinical Endocrinologists[J]. THYROID, 2011, 21(6):1-54.
[6] FRANKLYN J A, SHEPPARD M C, MAISONEUVE P. Thyroid function and mortality in patients treated for hyperthyroidism[J]. JAMA, 2005, 294(1): 71-80. [7] RON E, DOODY M M, BECKER D V, et al. Cancer mortality following treatment for adult hyperthyroidism[J]. JAMA, 1998, 280(4): 347-355.
[8] HAMBURGER J I. Management of hyperthyroidism in children and adolescents[J]. Chin Endoerinol Metab, 1985, 60(5): 1019-1024.
[9] RIVKEES S A, SKLAR C, FREEMARK M, et al. The management of Graves’disease in children, with special emphasis on radioiodine treatment[J]. Clin Endoerinol Metab, 1998, 83(11): 3767-3776.
[10] 葛均波, 徐永健. 内科学[M]. 北京: 人民卫生出版社, 2013: 691.
|